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Simple Summary: MET amplification is one of the resistance determinants after EGFR-TKI therapy
in EGFR mutant NSCLC. In this study, we evaluated the emergence of MET amplification after
EGFR-TKI treatment failure. The median progression-free survival associated with the most recent
EGFR-TKI treatment was shorter in MET amplification-positive patients than in negative patients.
Smoking history and less intracranial progression are associated with MET amplification. Suboptimal
responses with previous EGFR-TKI are associated with MET amplification. Proper MET amplification
screening for therapeutic targeting is needed.
Abstract: Objectives: Patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancer (NSCLC) ultimately acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) during treatment.
In 5–22% of these patients, resistance is mediated by aberrant mesenchymal epithelial transition factor
(MET) gene amplification. Here, we evaluated the emergence of MET amplification after EGFR-TKI
treatment failure based on clinical parameters. Materials and Methods: We retrospectively analyzed
186 patients with advanced EGFR-mutant NSCLC for MET amplification status by in situ hybridization
(ISH) assay after EGFR-TKI failure. We collected information including baseline patient characteristics,
metastatic locations and generation, line, and progression-free survival (PFS) of EGFR-TKI used before
MET evaluation. Multivariate logistic regression analysis was conducted to evaluate associations
between MET amplification status and clinical variables. Results: Regarding baseline EGFR mutations,
exon 19 deletion was predominant (57.5%), followed by L858R mutation (37.1%). The proportions
of MET ISH assays performed after first/second-generation and third-generation TKI failure were
66.7% and 33.1%, respectively. The median PFS for the most recent EGFR-TKI treatment was shorter in
MET amplification-positive patients than in MET amplification-negative patients (median PFS 7.0 vs.
10.4 months, p = 0.004). Multivariate logistic regression demonstrated that a history of smoking, short PFS
on the most recent TKI, and less intracranial progression were associated with a high probability of MET
amplification (all p < 0.05). Conclusions: Our results demonstrated the distinct clinical characteristics of
patients with MET amplification-positive NSCLC after EGFR-TKI therapy. Our clinical prediction can
aid physicians in selecting patients eligible for MET amplification screening and therapeutic targeting.
Keywords: non-small cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitor;
MET amplification
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1. Introduction
Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor re-
ceptor (EGFR) gene mutations are defined as an important targetable molecular subset [1].
First- or second-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies in previ-
ous trials have been shown to induce robust tumor regression that lasts for 9–12 months on
average [2,3]. In contrast, third-generation EGFR-TKIs, designed as antagonists to both
T790M-mutated EGFR and conventional EGFR mutations (exon 19 deletion and L858R
substitution), exhibit robust activity against T790M-mutant NSCLCs, showing progression
after first-line EGFR-TKI therapy, with a progression-free survival (PFS) of 8.5 months
and a prolonged PFS of 17.2 months in a upfront trial [4,5]. However, acquired resistance
is inevitable in most patients during the course of EGFR-TKI therapy, and the molecular
determinants of resistance are highly variable from patient to patient [6,7]. Moreover,
recent studies elucidated uncommon EGFR mutation and coexisting genetic alteration
might likely justify resistance to TKIs treatment. Different studies have assessed that the
uncommon EGFR mutation and concurrent presence of mutation provide worse progno-
sis in EGFR-positive NSCLC patients treated with first-, second-, and third-generation
TKIs [8,9].
Mesenchymal epithelial transition factor (MET) is a receptor for hepatocyte growth
factor (HGF) in mammalian cells and transduces growth factor signals to downstream
mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways through
tyrosine kinase activity [10]. Aberrant MET activation promotes cellular proliferation,
angiogenesis, and metastasis in many cancer types, including kidney, liver, stomach, breast,
and brain cancers. Importantly, amplification of the MET gene has been reported to be
involved in acquired resistance after EGFR-TKI therapy, accounting for 3–5% of resistance
to first/second-generation EGFR-TKIs [11,12]. Resistance after first-line osimertinib therapy
is even more enriched for MET amplification, which is the most common cause of resistance,
observed in 15% of all cases [13]. Interestingly, the recent TATTON trial demonstrated
the promising activity of the MET inhibitor salvolitinib in patients with MET-amplified
NSCLC, establishing MET amplification as the most important actionable target after
EGFR-TKI resistance besides T790M EGFR mutation [14,15]. However, the incidence of
MET amplification is considerably low, limiting routine MET in situ hybridization (ISH) or
mutation screening after EGFR-TKI failure.
NSCLC comprises heterogeneous molecular subtypes harboring mutations in various
oncogenes, including EGFR, ALK receptor tyrosine kinase (ALK), ROS proto-oncogene
1 (ROS1), RET, B-Raf proto-oncogene, and human epidermal growth factor receptor 2. Dur-
ing analysis of the “long-tail” distribution patterns of mutations, previous studies have
reported distinct clinicopathological characteristics of each genotype. For example, EGFR-
mutant NSCLC is highly prevalent in never-smokers and Asian populations [16]. ALK
rearrangement is associated with young patient age at diagnosis, signet ring cell pathol-
ogy, and bronchioalveolar involvement pattern [17]. These features have facilitated the
diagnosis of the different subtypes in clinical practice and enabled the focused molecular
investigation of a wide range of clinical presentations of NSCLC. Moreover, recent studies
have reported distinct clinical characteristics of patients with emergence of the T790M mu-
tation during EGFR-TKI therapy [18]. However, the clinicopathological characteristics of
MET-amplified NSCLC after EGFR-TKI failure have not been evaluated, and no predictive
factors for MET amplification have been reported.
Accordingly, in this study, we retrospectively analyzed 186 consecutive patients with
EGFR-mutant NSCLC who underwent MET ISH assays on rebiopsied tumors. We com-
pared the clinicopathological parameters and therapy responses for the previous EGFR-TKI
therapy between patients with MET-amplified and non-MET-amplified NSCLC. We ulti-
mately aimed to develop a clinical prediction method for MET amplification after EGFR-TKI
failure, which is an essential step for focused MET screening and subsequent therapeutic
MET targeting in patients.
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2. Methods
2.1. Patients
This study retrospectively analyzed 186 patients with advanced EGFR-mutant NSCLC
who progressed on EGFR-TKI therapy and underwent MET ISH assays at Yonsei Cancer
Center between April 2004 and March 2019. All patients received EGFR-TKI therapy, and post-
treatment tumor biopsy was performed after documented progression. The clinicopathological
data for the patients, including age, sex, smoking status, type of EGFR mutation, metastatic
site, line of EGFR-TKI therapy, type of EGFR-TKIs used, and PFS on previous EGFR-TKI, were
collected by electronic medical chart review. Informed consent for MET ISH analysis and use of
data was obtained at the time of rebiopsy. This study was approved by the institutional review
board of Severance Hospital (institutional review board approval No. 4-2019-0426).
2.2. Assessments
Chest computed tomography (CT) and abdominal CT were taken every 2–3 months
during treatment. Besides regular assessment follow-up, additional imaging was per-
formed according to the physician’s intention. The response to EGFR-TKI treatment was
radiologically assessed according to the Response Evaluation Criteria in Solid Tumors,
version 1.1. The objective response rate (ORR) was defined as the proportion of patients
with complete response (CR) or partial response (PR), and the disease control rate (DCR)
was defined as the proportion of patients with CR, PR, or stable disease. Progression-free
survival (PFS) was defined as the time from the start of EGFR-TKI treatment to disease
progression or death. Overall survival (OS) was defined as the start of TKI treatment
initiation to the date of death. In order to characterize OS based on treatment lines and
TKIs, we also measured OS from the date of MET ISH assays to the date of death.
2.3. EGFR Mutation and MET ISH Analyses
The diagnosis of NSCLC with non-squamous histology was confirmed by pathological
and radiological examination. In all patients, the EGFR mutation status was evaluated
using a PANA Mutyper detection kit. The MET amplification status was assessed using
MET VENTANA dual probe sliver ISH assays, defining a MET/CEP7 signal ratio of greater
than or equal to 2 or a MET average copy number in at least 50 enumerated cells of greater
than or equal to 5 as MET amplification positive [19].
2.4. Statistical Analysis
The categorical parameters were compared between MET amplification-positive and
-negative patients using chi-squared or Fisher’s exact tests as appropriate. Continuous
variables were compared using Student’s t-tests. The PFS and OS were estimated using
Kaplan–Meier curves, and subgroups were compared using log-rank tests. Logistic regres-
sion analyses were done to identify significant clinical factors predicting the emergence of
MET amplification after EGFR-TKI therapy in the study cohort. Statistical analyses were
performed with Statistical Package for Social Sciences (SPSS, Chicago, IL, USA) version
23.0 for Windows and GraphPad Prism version 8.0 (GraphPad Software, San Diego, CA,
USA). Two-sided p-values of less than or equal to 0.05 were considered significant.
3. Results
3.1. Clinicopathological Characteristics of the Study Population
In total, 186 patients with advanced EGFR-mutant NSCLC were enrolled; the majority of
patients were women (62.4%), and the median age was 61 years (range, 28–84 years). Most of
the patients were never smokers (67.2%), and 0.0 pack-years of smoking was the median for the
whole patient population. Regarding primary EGFR mutation status before MET ISH biopsy,
the existence of exon 19 deletion mutation was predominant (57.5%), followed by L858R
mutation (37.1%). Other mutations including Exon 20 insertion (p.A767_V769dup) (0.5%),
G719X (1.1%), L861Q (2.2%), S768I (1.1%), and G179S/L861Q (0.5%) also existed. Almost
all patients in the third-generation TKI cohort, except for six cases, had T790M mutation
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coexistence at the point of MET ISH assay owing to label use of third-generation TKIs in Korea.
The six cases excluded from this regulation included one with off-label use of osimertinib,
one with use of rociletinib during clinical trials (without T790M mutation), and three with
use of mavelertinib during clinical trials (without T790M mutation). The proportions of
MET ISH assays performed after first/second-generation (gefetinib, erlotinib, and afatinib)
or third-generation (osimertinib, olmutinib, rociletinib, mavelertinib, and lazertinib) TKI
failure were 66.7% and 33.3%, respectively. The proportions after failure of first-line and
later-line EGFR-TKIs were 44.1% and 55.9%, respectively. At baseline, 78 (41.9%) patients had
brain metastasis. At the time of MET ISH screening, 64 patients had progression of existing
intracranial lesions, and 39 patients progressed with new lesions in the brain. Additionally,
8.1% (n = 15) of patients had liver metastasis at baseline. Eleven patients showed progression
of existing lesions, and 28 patients had new liver metastasis at the time of rebiopsy.
MET amplification was identified in 30 (16.1%) of 186 patients. Patient characteristics
based on MET amplification status are shown in Table 1, Tables S1 and S2. No significant
differences in terms of patient characteristics, including sex, age, and liver metastasis status,
were observed between the two groups. In contrast, smoking status (p = 0.013), previous
TKI generation (p = 0.034), previous TKI line (p = 0.003), and intracranial progression at
the time of TKI failure (p < 0.001) showed significant differences between the two groups.
By the time of data lock (4 March 2021), 133 deaths (71.5%) had occurred, and 53 patients
(28.5%) were alive. The median follow-up duration for all patients was 65.4 months.
Table 1. Patient characteristics based on MET status (N = 186).
MET − (N = 156) MET + (N = 30)
N (%) N (%) p Value
Median age, years (range) 61 (28–84) 59 (28–76) 0.362
Sex
Male 57 (36.5%) 13 (43.3%)
Female 99 (63.5%) 17 (56.7%) 0.482
Smoking status
Current smoker 8 (5.1%) 1 (3.3%)
Ex-smoker 37 (23.7%) 15 (50.0%)
Never smoker 111 (71.2%) 14 (46.7%) 0.013
Median pack-year of smoking (interquartile range) 0.0 (0.0–9.5) 2.5 (0–21.0) 0.785
Previous TKI generation
First/second generation 109 (69.9%) 15 (50%)
Third generation 47 (30.1%) 15 (50%) 0.034
Previous TKI line
First line 93 (59.6%) 11 (36.7%)
Second line 58 (37.2%) 14 (46.7%)
Third line 5 (3.2%) 5 (16.7%) 0.003
Founder EGFR mutation
Exon 19 deletion 88 (56.4%) 19 (63.3%)
L858R 59 (37.8%) 10 (33.3%)
Other mutations ** 9 (5.8%) 1 (3.3%) 0.732
Liver metastases
No metastases 125 (80.1%) 18 (60.0%)
Baseline metastases without progression 1 (0.6%) 3 (10.0%)
Baseline metastases with progression 4 (2.6%) 7 (23.3%)
Progression with new lesion 26 (16.7%) 2 (6.7%) 0.185 *
Brain metastases
No metastases 44 (28.2%) 16 (53.3%)
Baseline metastases without progression 7 (4.5%) 7 (23.3%)
Baseline metastases with progression 59 (37.8%) 5 (16.7%)
Progression with new lesion 37 (23.7%) 2 (6.7%) <0.001 *
Not evaluated 9 (5.8%) 0 (0.0%)
MET, mesenchymal epithelial transition factor; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; * Between
progression versus no progression; ** Other mutations include exon 20 insertion (p.A767_V769dup) (N = 1), G719X (N = 2), L861Q (N = 4),
and S768I (N = 2) in MET (−) group and G179S/L861Q (N = 1) in MET (+) group.
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3.2. Treatment Outcomes of EGFR-TKIs According to MET Status
The median OS (calculated from the date of MET ISH assays) for the total popula-
tion was:
11.6 months (95% confidence interval [CI]: 9.7–13.5) (Figure 1A). The median OS
from the initiation of EGFR-TKI therapy was 39.2 months (95% CI: 33.6–44.8). Only slight
differences in the two OS attributes were observed after early initiation of EGFR-TKI
treatment in most patients. There were no significant differences in OS (from the initiation
of EGFR-TKI therapy) according to the MET amplification status (40.0 months [95% CI:
34.7–45.2] versus 34.7 months [95% CI: 21.5–47.88]; p = 0.53). However, it was difficult to
interpret the actual prognostic effects of MET status because some patients (n = 23) were
enrolled in MET inhibitor clinical trials.
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Figure 1. Kaplan–Meier plot for the entire study population. (A) Overall survival calculated from the date of MET ISH to 
the last follow-up date. (B) Progression-free survival of most recent tyrosine kinase inhibitor used. mOS, median overall 
survival; mPFS, median progression-free survival; CI, confidence interval; mon, month. 
The median PFS for the latest TKI in the total population was 10.2 months (95% CI: 
9.3–11.1) (Figure 1B). Because of differences in PFS between first-/second- and third-gen-
eration TKIs, we analyzed these drugs separately. For patients receiving first-/second-
generation TKIs, PFS was significantly shorter in the MET-positive group than in the neg-
ative group (7.0 versus 10.4 months; p = 0.003). However, in the third-generation TKI 
group, there were no significant differences in PFS (7.2 versus 11.0 months; p = 0.163), and 
only similar trends were observed (Figure 2). 
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The median PFS for the latest TKI in the total population was 10.2 months (95%
CI: 9.3–11.1) (Figure 1B). Because of differences in PFS between first-/second- and third-
generation TKIs, we analyzed these drugs separately. For patients receiving first-/second-
generation TKIs, PFS was significantly shorter in the MET-positive group than in the
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negative group (7.0 versus 10.4 months; p = 0.003). However, in the third-generation TKI
group, there were no significant differences in PFS (7.2 versus 11.0 months; p = 0.163), and
only similar trends were observed (Figure 2).
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(hazard ratio [HR]: 3.475, 95% CI: 1.326–8.440; p = 0.011), PFS of most recent TKI (HR: 
0.898, 95% CI: 0.833–0.967; p = 0.004), and intracranial progression status (HR: 0.138, 95% 
CI: 0.051–0.347; p < 0.001) as significant variables. The presence of smoking history, short 
PFS on latest TKI, and no intracranial progression at EGFR-TKI failure were associated 
with a high probability of MET amplification emergence. 
The T790M mutation was not included in the logistic regression analysis. The reason 
is that in the case of acquiring the T790M mutation, since most of the patients were ad-
ministered the 3rd generation TKI, multicollinearity occurred between the two variables. 
Table 2. Logistic regression analysis of clinical factors predicting MET amplified status. 
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Figure 2. Kaplan-Meier plot of the progression-free survival (PFS) stratified by MET amplification status. (A) PFS of 1st/2nd
generation tyrosine kinase inhibitor cohort. (B) PFS of 3rd generation tyrosine kinase inhibitor cohort. MET, mesenchymal
epithelial transition factor; CI, confidence interval; mon, month.
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3.3. Potential Predictors for MET Amplification
Table 2 shows the results of univariate and multivariate analysis by a logistic regression
model to determine the predictive factors for MET amplification. Univariate analysis
showed that smoking status, TKI generation, lines of EGFR-TKI therapy, PFS of the most
recent TKI, and brain metastasis status at presentation were significant predictive factors.
However, multivariate analysis considering all covariables identified only smoking status
(hazard ratio [HR]: 3.475, 95% CI: 1.326–8.440; p = 0.011), PFS of most recent TKI (HR: 0.898,
95% CI: 0.833–0.967; p = 0.004), and intracranial progression status (HR: 0.138, 95% CI:
0.051–0.347; p < 0.001) as significant variables. The presence of smoking history, short PFS
on latest TKI, and no intracranial progression at EGFR-TKI failure were associated with a
high probability of MET amplification emergence.
Table 2. Logistic regression analysis of clinical factors predicting MET amplified status.
Category
Univariate Multivariate
HR 95% CI p Value HR 95% CI p Value
Age 0.983 0.948–1.020 0.360 - - -
Sex (male versus female) 0.753 0.341–1.663 0.483 - - -
Smoking status (never versus ex- or
current smoker) 2.819 1.271–6.252 0.011 3.346 1.326–8.442 0.011
TKI generation (first/second versus third) 2.319 1.049–5.126 0.038 2.618 1.044–6.565 0.040
Baseline EGFR mutation site
Exon 19 deletion 1
L858R 0.785 0.341–1.807 0.569 - - -
Other mutations * 0.515 0.061–4.307 0.540 - - -
PFS of most recent TKI 0.930 0.875–0.988 0.019 0.898 0.835–0.965 0.004
Liver metastases (no PD versus PD) 1.800 0.749–4.325 0.189 - - -
Brain metastases (no PD versus PD) 0.162 0.065–0.402 <0.001 0.139 0.052–0.373 <0.001
HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; PFS, progression-free
survival; PD, progression of disease. * Other mutations; exon 20 insertion (p.A767_V769dup), G719X, G719S/L861Q, L861Q, and S768I.
The T790M mutation was not included in the logistic regression analysis. The reason
is that in the case of acquiring the T790M mutation, since most of the patients were
administered the 3rd generation TKI, multicollinearity occurred between the two variables.
3.4. Characteristics of Patients with MET Amplification
We further investigated the characteristics of patients with MET amplification (n = 30)
based on the most recent TKI outcomes and progression site (Table 3). The ORR of
first/second-generation TKIs was 73.3%, which was numerically higher than that of third-
generation TKIs (53.3%), although the difference was not significant (p = 0.26). Additionally,
the DCRs of the most recent first-/second-generation and third-generation TKIs were 93.3%
and 80%, respectively (p = 0.29). Regarding the PFS of the most recent TKI, there were
no differences between the first/second-generation group and the third-generation group
(7.0 versus 7.2 month; p = 0.15). The treatment PFS of the most recent TKI and the best
responses are shown in Figure 3.
There was no metastatic tropism of MET-amplified cancer during progression after
EGFR-TKI therapy. The most common site of progression was primary lung lesions
(n = 23), followed by intrathoracic lesions, which were indicative of lymph node, pleura,
and secondary lung metastases (n = 17). Among the biopsy sites from which MET-amplified
tissue was obtained, lung lesions were the most frequent site for rebiopsy (n = 17), followed
by the liver because of its easy accessibility. The intrathoracic lymph node, extrathoracic
lymph node, and skin were the rest of the sites for rebiopsy, as shown in Figure S1.
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Table 3. Overall response based on latest TKIs of MET-positive patients (N = 30).
Treatment Response PD Site
Tyrosine Kinase








Lung Intrathoracic Liver Bone Extrathoracic Brain
First-generation
TKI 8
1L 6 Pts (75.0%)
2L 1 Pts (12.5%)
3L 1 Pts (12.5%)
PR 6 Pts (75.0%)
SD 1 Pts (12.5%)





(NR) 7 (87.5%) 7 (87.5%) 4 (50.0%) 1 (12.5%) 1 (12.5%) 0
Gefitinib 5 ORR 60.0%/DCR 80.0% 5.1 months(3.7–6.4) NR 4 (80.0%) 5 (100%) 3 (60.0%) 0 1 (20%) 1 (20%)
Erlotinib 3 ORR 100%/DCR 100% 5.2 months(3.5–6.9)
18.7 months




7 1L 5 Pts (71.4%)2L 2 Pts (28.6%)
PR 5 Pts (71.4%)









15 2L 12 Pts (80.0%)3L 3 Pts (20.0%)
PR 8 Pts (53.3%)
SD 4 Pts (26.7%)





(31.0–46.6) 12 (80%) 7 (46.7%) 3 (20%) 3 (20%) 6 (40%) 4 (26.7%)
Osimertinib 12 ORR 58.3%/DCR 83.3% 7.2 months(4.8–9.6)
34.7 months
(27.6–42.0) 9 (13.3%) 6 (50%) 2 (16.7%) 3 (25%) 5 (41.7%) 3 (25%)
Olmutinib 1 ORR 100%/DCR 100% 18.0 months 74.0 months 1 (100%) 1 (100%) 1 (100%) 0 0 1 (100%)
Lazertinib 2 ORR 0%/DCR 50.0% 1.7 months(NR)
17.0 months
(NR) 2 (100%) 0 0 0 1 (50%) 0
ORR, overall response rate; DCR, disease control rate; PFS, progression-free survival; CI, confidence interval; L, line; Pts, patients; PR, partial response; SD, stable disease; PD, progressive disease; NR, not reached.
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4. Discussion
Predictive genomic markers, particularly EGFR mutant status, are indicative of the
efficacy of EGFR-TKI therapy in advanced NSCLC and are now routinely evaluated in
clinical practice [20]. Additionally, after acquisition of resistance to first/second-generation
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EGFR-TKIs, it is now considered routine practice to rebiopsy the progression site for T790M
mutation by locked nucleic acid-based assays to determine whether initiation of third-
generation EGFR-TKIs is appropriate [21,22]. Because the T790M mutation is the most
common mechanism (50–60%) for acquired resistance to first/second-generation TKIs,
it is rational to screen for the presence of this mutation routinely [23]. However, other
determinants of resistance cannot be as easily screened since they are so rare [24,25].
In our study, the proportion of MET-positive patients was 16.1%; in the first/second-
generation and third-generation TKI failure groups, 12.1% and 24.2% of patients were
positive for MET, respectively, consistent with previous studies [13,24–26]. Despite the
limitations of our study as a single-center study of an unselected EGFR mutant lung cancer
cohort, this consistent proportion of MET amplification as determinant of resistance makes
it reasonable to find the enriched population to evaluate. To the best of our knowledge,
this is the first MET ISH study to confine its scope to patients who developed resistance to
prior EGFR-TKI failure, which we commonly encounter in our clinical practice. Although
first-line osimertinib treatment is the standard of care in many countries, in Korea, it is not
often selected as 1st line TKI because it is not covered by the National Insurance Service of
Korea health insurance. Thus, this point should be considered because it is unclear whether
the characteristics of the present patients are predictive of MET amplification in resistance
after first-line therapy in osimertinib.
In this study, MET positivity occurred more frequently in ever-smokers who had a
history of tobacco use than in never-smokers. Typically, other driver mutations (e.g., EGFR,
ALK, and ROS) of lung cancer tend to occur in never-smokers [17,27,28]. Some reports have
described a high incidence of ever-smokers in patients with MET exon 14 mutation [29,30]
and in patients with MET amplification [31]. However, another study assumed that patients
with MET exon 14 mutations whose smoking statuses were not known would be mostly
never-smokers owing to their low tumor mutation burden [29]. Although further compre-
hensive profiling of patients with MET amplifications is needed, considering real-world
data, it is reasonable to screen patients with a history of tobacco use for MET amplification.
Lung cancer easily metastasizes to the brain; indeed, 10–50% of all patients with lung
cancer develop brain metastases during their disease course [32,33]. Moreover, patients
with ALK-positive lung cancer have a higher incidence of brain metastasis, whereas patients
with ROS1-positive lung cancer have a lower incidence [34–36]. To date, no data have de-
scribed the preferred metastatic site of MET-positive lung cancer after previous TKI failure.
A recent study in a treatment-naïve population showed that there were no differences in
the presence of brain metastasis between MET-high and MET-low patients, as defined
by copy number gain [37]. However, in our study, tropism toward the brain was less
prominent in patients with MET amplification than in patients without amplification. Our
findings suggested a need to identify pathways other than MET amplification as resistance
mechanisms associated with EGFR-TKI failure in patients having brain metastasis.
Last but not least we found a significant tendency toward a shorter PFS for the most
recent TKI in patients with MET amplification compared with that in patients without
amplification. Some reports have shown that various oncogenic MET-driven cancers
are associated with poor prognoses [38–40]. However, few studies have evaluated PFS
associated with previous EGFR-TKIs in patients with MET amplification. A recent study of
treatment-naïve EGFR mutant lung cancer showed that there were no differences in time to
treatment failure (TTF) between two groups distinguished according to MET copy number.
Instead, patients with MET amplification showed short TTF and poor outcomes (median
TTF: 5 months; range, 1.0–6.4 months) [37]. Although different populations and parameters
were used, our results were consistent with the previous results in terms of the shorter PFS
in patients with MET amplification. Overall, we believe that it is reasonable to perform
MET ISH in patients who show suboptimal responses to previous EGFR-TKIs in practice.
Clear-cut relationships between MET amplification, mutation, and overexpression
have not yet been confirmed when collectively applied as predictive markers for MET-
targeting therapy. Owing to failed results of clinical trials in which patients with MET-
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overexpressing tumors, measured by immunohistochemistry of MET protein, were en-
rolled [41], the preferred biomarker for recent MET-TKI clinical trials is gene amplifica-
tion [15,42]. In addition to codrivers in NSCLC, MET mutations are generally thought to be
mutually exclusive with mutations in other major lung cancer drivers and have not been
shown to be associated with acquired resistance to EGFR-TKI therapy [43]. Because the
de novo prevalence of MET amplification [44,45] and overlap by verifying degrees with
other oncogenic drivers [46] are confounding factors that need to be studied in greater
detail, our MET ISH results for EGFR-TKI-resistant lung cancer have clinical relevance in
routine practice.
This study provided the largest series of MET analysis data in patients with lung
cancer who developed resistance after EGFR-TKI therapy. However, there are still several
limitations to this study. Given the retrospective nature of the study and the heterogeneity
of the real world, this study was subject to potential biases. Additionally, because of the
low discovery rate of MET positivity and the diversity of treatments, it was difficult to
perform well-controlled analyses. Therefore, additional studies based on stratification of
the generation of EGFT-TKIs and line of therapy should be conducted.
In conclusion, our results revealed the distinct clinical characteristics of patients with
MET amplification-positive NSCLC after acquisition of resistance to EGFR-TKI therapy.
Although MET amplified NSCLC is rare, our clinical predictions could aid physicians in
identifying patients eligible for MET amplification screening and therapeutic targeting.
Further efforts are required to standardize the diagnostic method and improve patient
access to screening.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers13123096/s1, Figure S1: Rebiopsied sites for MET ISH assays, Table S1: Patient
characteristics based on MET status (first/second generation cohort, N = 124), Table S2. Patient
characteristics based on MET status (third generation cohort, N = 62).
Author Contributions: Conceptualization, B.-C.A. and J.H.L.; methodology, B.-C.A. and J.H.L.;
software, B.-C.A. and J.H.L.; validation, K.-H.P.; formal analysis, B.-C.A. and J.H.L.; investigation,
B.-C.A. and J.H.L.; resources, B.-C.A., M.H.K., K.-H.P., C.-k.L., S.M.L., H.R.K., B.C.C. and M.H.H.; data
curation, B.-C.A. and J.H.L.; writing—original draft preparation B.-C.A. and J.H.L.; writing—review
and editing, M.H.H.; visualization, B.-C.A. and J.H.L.; supervision, M.H.H.; project administration
B.C.C. and M.H.H.; funding acquisition, B.C.C. All authors have read and agreed to the published
version of the manuscript.
Funding: No specific funding was disclosed.
Institutional Review Board Statement: The study protocol adhered to the ethical guidelines of
the 1975 Declaration of Helsinki and was approved by the institutional review board of Severance
Hospital (institutional review board approval No. 4-2019-0426).
Informed Consent Statement: The requirement for written informed consent was waived, given the
retrospective nature of the study.
Data Availability Statement: The data that support the findings of this study are available from the
corresponding author upon reasonable request.
Acknowledgments: We thank all of the patients, the investigators, research nurses, and operations
staff who participated in this study.
Conflicts of Interest: The authors have no conflict of interest to disclose.
References
1. Rosell, R.; Bivona, T.G.; Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382,
720–731. [CrossRef]
2. Mok, T.S.; Wu, Y.; Thongprasert, S.; Yang, C.; Chu, D.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Nishiwaki, Y.; et al.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947–957. [CrossRef]
Cancers 2021, 13, 3096 12 of 14
3. Park, K.; Tan, E.H.; O’Byrne, K.; Zhang, L.; Boyer, M.; Mok, T.; Hirsh, V.; Yang, J.h.; Lee, K.H.; Lu, S.; et al. Afatinib versus gefitinib
as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label,
randomised controlled trial. Lancet Oncol. 2016, 17, 577–589. [CrossRef]
4. Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.;
Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med.
2018, 378, 113–125. [CrossRef] [PubMed]
5. Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.;
et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N. Engl. J. Med. 2017, 376, 629–640. [CrossRef]
[PubMed]
6. Oxnard, G.R.; Hu, Y.; Mileham, K.F.; Husain, H.; Costa, D.B.; Tracy, P.; Feeney, N.; Sholl, L.M.; Dahlberg, S.E.; Redig, A.J.;
et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and
Acquired Resistance to Osimertinib. JAMA Oncol. 2018, 4, 1527–1534. [CrossRef] [PubMed]
7. Lim, S.M.; Syn, N.L.; Cho, B.C.; Soo, R.A. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms
and therapeutic strategies. Cancer Treat. Rev. 2018, 65, 1–10. [CrossRef]
8. Gristina, V.; La Mantia, M.; Galvano, A.; Cutaia, S.; Barraco, N.; Castiglia, M.; Perez, A.; Bono, M.; Iacono, F.; Greco, M. Non-Small
Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double
Dilemma. J. Mol. Pathol. 2021, 2, 173–196. [CrossRef]
9. Gristina, V.; Malapelle, U.; Galvano, A.; Pisapia, P.; Pepe, F.; Rolfo, C.; Tortorici, S.; Bazan, V.; Troncone, G.; Russo, A. The
significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and
critical appraisal. Cancer Treat. Rev. 2020, 85, 101994. [CrossRef] [PubMed]
10. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Vande Woude, G. Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer
2012, 12, 89–103. [CrossRef] [PubMed]
11. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.;
et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039–1043.
[CrossRef] [PubMed]
12. Yu, H.A.; Arcila, M.E.; Rekhtman, N.; Sima, C.S.; Zakowski, M.F.; Pao, W.; Kris, M.G.; Miller, V.A.; Ladanyi, M.; Riely, G.J.
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung
cancers. Clin. Cancer Res. 2013, 19, 2240–2247. [CrossRef]
13. Ramalingam, S.S.; Cheng, Y.; Zhou, C.; Ohe, Y.; Imamura, F.; Cho, B.C.; Lin, M.; Majem, M.; Shah, R.; Rukazenkov, Y.; et al.
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Ann. Oncol. 2018,
29 (Suppl. 9), 173–178. [CrossRef]
14. Gan, H.K.; Millward, M.J.; Hua, Y.; Qi, C.; Sai, Y.; Su, W.; Wang, J.; Zhang, L.; Frigault, M.M.; Morgan, S.; et al. First-in-Human
Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and
Anti-Tumor Activity. Clin. Cancer Res. 2019. [CrossRef]
15. Yu, H.; Ahn, M.-J.; Kim, S.-W.; Cho, B.C.; Sequist, L.; Orlov, S.; Ottesen, L.H.; Verheijen, R.B.; Mellemgaard, A.; Wessen, J.;
et al. Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant,
MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI). In Proceedings of the AACR Annual Meeting, Atlanta, GA, USA, 29 March–3 April 2019.
16. Lee, Y.J.; Kim, J.H.; Kim, S.K.; Ha, S.J.; Mok, T.S.; Mitsudomi, T.; Cho, B.C. Lung cancer in never smokers: Change of a mindset in
the molecular era. Lung Cancer 2011, 72, 9–15. [CrossRef]
17. Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.;
McDermott, U.; et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin.
Oncol. 2009, 27, 4247–4253. [CrossRef]
18. Wang, S.; Yan, B.; Zhang, Y.; Xu, J.; Qiao, R.; Dong, Y.; Zhang, B.; Zhao, Y.; Zhang, L.; Qian, J.; et al. Different characteristics
and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Int. J. Cancer 2019, 144,
2880–2886. [CrossRef] [PubMed]
19. Oxnard, G.R.; Yang, J.C.H.; Yu, H.; Kim, S.W.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Mann, H.; Thress, K.S.; et al. TATTON: A
multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Ann. Oncol. 2020, 31, 507–516. [CrossRef]
20. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko,
J.G.; Haluska, F.G.; et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of
Non–Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139. [CrossRef] [PubMed]
21. Arcila, M.E.; Oxnard, G.R.; Nafa, K.; Riely, G.J.; Solomon, S.B.; Zakowski, M.F.; Kris, M.G.; Pao, W.; Miller, V.A.; Ladanyi, M.
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation
Using a Locked Nucleic Acid-Based Assay. Clin. Cancer Res. 2011, 17, 1169–1180. [CrossRef]
22. Cross, D.A.E.; Ashton, S.E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C.A.; Spitzler, P.J.; Orme, J.P.; Finlay, M.R.V.; Ward, R.A.; Mellor,
M.J.; et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer.
Cancer Discov. 2014, 4, 1046–1061. [CrossRef] [PubMed]
Cancers 2021, 13, 3096 13 of 14
23. Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Jänne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos,
B. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2005, 352, 786–792. [CrossRef]
[PubMed]
24. Nagano, T.; Tachihara, M.; Nishimura, Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase
Inhibitors and a Potential Treatment Strategy. Cells 2018, 7. [CrossRef]
25. Ortiz-Cuaran, S.; Scheffler, M.; Plenker, D.; Dahmen, l.; Scheel, A.H.; Fernandez-Cuesta, L.; Meder, L.; Lovly, C.M.; Persigehl,
T.; Merkelbach-Bruse, S.; et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR
Inhibitors. Clin. Cancer Res. 2016, 22, 4837–4847. [CrossRef]
26. Loriot, Y.; Planchard, D.; André, F.; Gobert, A.; Soria, J.C.; Auger, N.; Lacroix, L. EGFR-independent mechanisms of acquired
resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 2015, 26, 2073–2078. [CrossRef]
27. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; et al. EGF receptor
gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and
erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306–13311. [CrossRef]
28. Bergethon, K.; Shaw, A.T.; Ou, S.H.; Katayama, R.; Lovly, C.M.; McDonald, N.T.; Massion, P.P.; Siwak-Tapp, C.; Gonzalez, A.;
Fang, R.; et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012, 30, 863–870. [CrossRef]
29. Schrock, A.B.; Frampton, G.M.; Suh, J.; Chalmers, Z.R.; Rosenzweig, M.; Erlich, R.L.; Halmos, B.; Goldman, J.; Forde, P.;
Leuenberger, K.; et al. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. J. Thorac.
Oncol. 2016, 11, 1493–1502. [CrossRef]
30. Awad, M.M.; Oxnard, G.R.; Jackman, D.M.; Savukoski, D.O.; Hall, D.; Shivdasani, P.; Heng, J.C.; Dahlberg, S.E.; Janne, P.A.; Verma,
S.; et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET
Genomic Amplification and c-Met Overexpression. J. Clin. Oncol. 2016, 34, 721–730. [CrossRef]
31. Bubendorf, L.; Dafni, U.; Schöbel, M.; Finn, S.P.; Tischler, V.; Sejda, A.; Marchetti, A.; Thunnissen, E.; Verbeken, E.K.; Warth, A.;
et al. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the
European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 2017, 111, 143–149. [CrossRef]
32. Sørensen, J.B.; Hansen, H.H.; Hansen, M.; Dombernowsky, P. Brain metastases in adenocarcinoma of the lung: Frequency, risk
groups, and prognosis. J. Clin. Oncol. 1988, 6, 1474–1480. [CrossRef]
33. Villano, J.L.; Durbin, E.B.; Normandeau, C.; Thakkar, J.P.; Moirangthem, V.; Davis, F.G. Incidence of brain metastasis at initial
presentation of lung cancer. Neuro Oncol. 2014, 17, 122–128. [CrossRef]
34. Soria, J.C.; Tan, D.S.W.; Chiari, R.; Wu, Y.L.; Paz-Ares, L.; Wolf, J.; Geater, S.L.; Orlov, S.; Cortinovis, D.; Yu, C.J.; et al. First-
line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A
randomised, open-label, phase 3 study. Lancet 2017, 389, 917–929. [CrossRef]
35. Gainor, J.F.; Tseng, D.; Yoda, S.; Dagogo-Jack, I.; Friboulet, L.; Lin, J.J.; Hubbeling, H.G.; Dardaei, L.; Farago, A.F.; Schultz, K.R.;
et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
JCO Precis. Oncol. 2017, 2017. [CrossRef]
36. Park, S.; Ahn, B.C.; Lim, S.W.; Sun, J.M.; Kim, H.R.; Hong, M.H.; Lee, S.H.; Ahn, J.S.; Park, K.; Choi, Y.; et al. Characteristics and
Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J. Thorac. Oncol. 2018, 13, 1373–1382.
[CrossRef] [PubMed]
37. Lai, G.G.Y.; Lim, T.H.; Lim, J.; Liew, P.J.R.; Kwang, X.L.; Nahar, R.; Aung, Z.W.; Takano, A.; Lee, Y.Y.; Lau, D.P.X.; et al. Clonal
MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant
Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2019, 37, 876–884. [CrossRef]
38. Catenacci, D.V.; Ang, A.; Liao, W.L.; Shen, J.; O’Day, E.; Loberg, R.D.; Cecchi, F.; Hembrough, T.; Ruzzo, A.; Graziano, F. MET
tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Cancer 2017, 123, 1061–1070. [CrossRef] [PubMed]
39. Go, H.; Jeon, Y.K.; Park, H.J.; Sung, S.W.; Seo, J.W.; Chung, D.H. High MET gene copy number leads to shorter survival in patients
with non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 305–313. [CrossRef]
40. Tong, J.H.; Yeung, S.F.; Chan, A.W.H.; Chung, L.Y.; Chau, S.L.; Lung, R.W.M.; Tong, C.Y.; Chow, C.; Tin, E.K.Y.; Yu, Y.H.; et al.
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma
with Poor Prognosis. Clin. Cancer Res. 2016, 22, 3048–3056. [CrossRef]
41. Spigel, D.R.; Edelman, M.J.; O’Byrne, K.; Paz-Ares, L.; Mocci, S.; Phan, S.; Shames, D.S.; Smith, D.; Yu, W.; Paton, V.E.; et al.
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or
IV Non-Small-Cell Lung Cancer: METLung. J. Clin. Oncol. 2017, 35, 412–420. [CrossRef]
42. Wu, Y.L.; Zhang, L.; Kim, D.W.; Liu, X.; Lee, D.H.; Yang, J.C.; Ahn, M.J.; Vansteenkiste, J.F.; Su, W.C.; Felip, E.; et al. Phase Ib/II
Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2018, 36, 3101–3109.
[CrossRef]
43. Onozato, R.; Kosaka, T.; Kuwano, H.; Sekido, Y.; Yatabe, Y.; Mitsudomi, T. Activation of MET by gene amplification or by splice
mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 2009, 4, 5–11. [CrossRef]
[PubMed]
Cancers 2021, 13, 3096 14 of 14
44. Okuda, K.; Sasaki, H.; Yukiue, H.; Yano, M.; Fujii, Y. Met gene copy number predicts the prognosis for completely resected
non-small cell lung cancer. Cancer Sci. 2008, 99, 2280–2285. [CrossRef] [PubMed]
45. Cappuzzo, F.; Marchetti, A.; Skokan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; Grammastro, M.d.; Sciarrotta, M.G.; Buttitta, F.;
Incarbone, M.; et al. Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell
Lung Cancer Patients. J. Clin. Oncol. 2009, 27, 1667–1674. [CrossRef] [PubMed]
46. Noonan, S.A.; Berry, L.; Lu, X.; Gao, D.; Barón, A.E.; Chesnut, P.; Sheren, J.; Aisner, D.L.; Merrick, D.; Doebele, R.C.; et al.
Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene
Overlap Analysis. J. Thorac. Oncol. 2016, 11, 1293–1304. [CrossRef] [PubMed]
